Chemotherapy, not androgen receptor-targeted therapy should be used upfront for metastatic hormone-sensitive prostate cancer. PRO: docetaxel chemotherapy should be the default consideration in metastatic hormone-sensitive prostate cancer

Edmond M. Kwan; Arun A. Azad

doi:10.1097/MOU.0000000000000777

Chemotherapy, not androgen receptor-targeted therapy should be used upfront for metastatic hormone-sensitive prostate cancer. PRO: docetaxel chemotherapy should be the default consideration in metastatic hormone-sensitive prostate cancer

Edmond M. Kwan, Arun A. Azad

Medicine Monash Health

Research output: Contribution to journal › Article › Other › peer-review

1 Citation (Scopus)

Original language	English
Pages (from-to)	617-619
Number of pages	3
Journal	Current Opinion in Urology
Volume	30
Issue number	4
DOIs	https://doi.org/10.1097/MOU.0000000000000777
Publication status	Published - 1 Jul 2020

Access to Document

10.1097/MOU.0000000000000777

Link to publication in Scopus

Cite this

@article{991d514573b646298cc6acfbf6b2e989,

title = "Chemotherapy, not androgen receptor-targeted therapy should be used upfront for metastatic hormone-sensitive prostate cancer. PRO: docetaxel chemotherapy should be the default consideration in metastatic hormone-sensitive prostate cancer",

author = "Kwan, {Edmond M.} and Azad, {Arun A.}",

year = "2020",

month = jul,

day = "1",

doi = "10.1097/MOU.0000000000000777",

language = "English",

volume = "30",

pages = "617--619",

journal = "Current Opinion in Urology",

issn = "0963-0643",

publisher = "Lippincott Williams & Wilkins",

number = "4",

}

Chemotherapy, not androgen receptor-targeted therapy should be used upfront for metastatic hormone-sensitive prostate cancer. PRO : docetaxel chemotherapy should be the default consideration in metastatic hormone-sensitive prostate cancer. / Kwan, Edmond M.; Azad, Arun A.

In: Current Opinion in Urology, Vol. 30, No. 4, 01.07.2020, p. 617-619.

Research output: Contribution to journal › Article › Other › peer-review

TY - JOUR

T1 - Chemotherapy, not androgen receptor-targeted therapy should be used upfront for metastatic hormone-sensitive prostate cancer. PRO

T2 - docetaxel chemotherapy should be the default consideration in metastatic hormone-sensitive prostate cancer

AU - Kwan, Edmond M.

AU - Azad, Arun A.

PY - 2020/7/1

Y1 - 2020/7/1

UR - http://www.scopus.com/inward/record.url?scp=85085586039&partnerID=8YFLogxK

U2 - 10.1097/MOU.0000000000000777

DO - 10.1097/MOU.0000000000000777

M3 - Article

C2 - 32452996

AN - SCOPUS:85085586039

VL - 30

SP - 617

EP - 619

JO - Current Opinion in Urology

JF - Current Opinion in Urology

SN - 0963-0643

IS - 4

ER -